

**REMARKS****Amendments to the Claims**

Claims 1-5 and 26 are pending. The Applicants respectfully ask the Examiner to replace all prior versions and listings of claims in the present application with the listing of claims currently provided. Claims 1 and 5 were amended. The Applicants hereby state that the amendments to the claims do not add new subject matter to the specification.

Support for the amendments made to Claim 1 can be found at, e.g., pg. 25, lines 12-16.

***Claim Objections***

The Examiner has objected to Claims 1-5 and 26 for encompassing non-elected subject matter because the present claims are directed to inhibiting IGF-1 (the elected species) and IGF-2 (a non-elected species).

The Applicants submit that amended Claim 1 is directed only to the elected species. Therefore, the Applicants respectfully request withdrawal of the objection against Claims 1-5, and 26.

**Rejections Pursuant to 35 U.S.C. § 112, ¶ 2 Indefiniteness*****Extended***

The Examiner has rejected Claims 1-5, and 26 as allegedly being indefinite under 35 U.S.C. § 112, ¶ 2 because "extending" is a relative term and there is no standard or point of reference for which the period of paralysis is considered to be extended. The Applicants respectfully ask for reconsideration under 37 C.F.R. § 1.116.

The Applicants submit that amended Claim 1 recites the point of reference "as compared to treatment with clostridial toxin alone." As such, the term "extended is definite. Therefore,

the Applicants respectfully request withdrawal of the 35 U.S.C. § 112, ¶ 2 indefiniteness rejection against Claims 1-5, and 26.

***Botulinum neurotoxin***

The Examiner has rejected Claim 5 as allegedly being indefinite under 35 U.S.C. § 112, ¶ 2 because "said botulinum neurotoxin" lacks antecedent basis. The Applicants respectfully ask for reconsideration under 37 C.F.R. § 1.116.

The Applicants submit that amended Claim 5 recites "said clostridial neurotoxin," and has antecedent basis to Claim 1. Therefore, the Applicants respectfully request withdrawal of the 35 U.S.C. § 112, ¶ 2 indefiniteness rejection against Claim 5.

**CONCLUSION**

For the above reasons the Applicants respectfully submit that the claims are in condition for allowance, and the Applicants respectfully urge the Examiner to issue a Notice to that effect. The Examiner is invited to call the undersigned agent if there are any questions. Please use Deposit Account 01-0885 for the payment of any extension of time fees under 37 C.F.R. § 1.136 or any other fees due in connection with the current response.

Respectfully submitted,

/Dean G. Stathakis/

Dean G. Stathakis, Ph.D.  
Registration No. 54,465  
Agent of Record



**ALLERGAN**

**LEGAL DEPARTMENT**

2525 Dupont Drive  
Irvine, California 92612-1599  
Tel: 714/246-6521  
Fax: 714/246-4249